These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Long-term enzymatic and phenotypic correction in the phenylketonuria mouse model by adeno-associated virus vector-mediated gene transfer. Oh HJ; Park ES; Kang S; Jo I; Jung SC Pediatr Res; 2004 Aug; 56(2):278-84. PubMed ID: 15181195 [TBL] [Abstract][Full Text] [Related]
4. Gene therapy for phenylketonuria: phenotypic correction in a genetically deficient mouse model by adenovirus-mediated hepatic gene transfer. Fang B; Eisensmith RC; Li XH; Finegold MJ; Shedlovsky A; Dove W; Woo SL Gene Ther; 1994 Jul; 1(4):247-54. PubMed ID: 7584088 [TBL] [Abstract][Full Text] [Related]
5. Administration-route and gender-independent long-term therapeutic correction of phenylketonuria (PKU) in a mouse model by recombinant adeno-associated virus 8 pseudotyped vector-mediated gene transfer. Ding Z; Georgiev P; Thöny B Gene Ther; 2006 Apr; 13(7):587-93. PubMed ID: 16319947 [TBL] [Abstract][Full Text] [Related]
7. State-of-the-Art 2019 on Gene Therapy for Phenylketonuria. Grisch-Chan HM; Schwank G; Harding CO; Thöny B Hum Gene Ther; 2019 Oct; 30(10):1274-1283. PubMed ID: 31364419 [TBL] [Abstract][Full Text] [Related]
8. Metabolic basis of sexual dimorphism in PKU mice after genome-targeted PAH gene therapy. Chen L; Thung SN; Woo SL Mol Ther; 2007 Jun; 15(6):1079-85. PubMed ID: 17406346 [TBL] [Abstract][Full Text] [Related]
9. Long-term correction of hyperphenylalaninemia by AAV-mediated gene transfer leads to behavioral recovery in phenylketonuria mice. Mochizuki S; Mizukami H; Ogura T; Kure S; Ichinohe A; Kojima K; Matsubara Y; Kobayahi E; Okada T; Hoshika A; Ozawa K; Kume A Gene Ther; 2004 Jul; 11(13):1081-6. PubMed ID: 15057263 [TBL] [Abstract][Full Text] [Related]
10. Complete restoration of phenylalanine oxidation in phenylketonuria mouse by a self-complementary adeno-associated virus vector. Yagi H; Ogura T; Mizukami H; Urabe M; Hamada H; Yoshikawa H; Ozawa K; Kume A J Gene Med; 2011 Feb; 13(2):114-22. PubMed ID: 21322099 [TBL] [Abstract][Full Text] [Related]
11. Reversal of gene expression profile in the phenylketonuria mouse model after adeno-associated virus vector-mediated gene therapy. Oh HJ; Lee H; Park JW; Rhee H; Koo SK; Kang S; Jo I; Jung SC Mol Genet Metab; 2005 Dec; 86 Suppl 1():S124-32. PubMed ID: 16150627 [TBL] [Abstract][Full Text] [Related]
12. Expression of human phenylalanine hydroxylase activity in T lymphocytes of classical phenylketonuria children by retroviral-mediated gene transfer. Lin CM; Tan Y; Lee YM; Chang CC; Hsiao KJ J Inherit Metab Dis; 1997 Nov; 20(6):742-54. PubMed ID: 9427141 [TBL] [Abstract][Full Text] [Related]
13. A novel Pah-exon1 deleted murine model of phenylalanine hydroxylase (PAH) deficiency. Richards DY; Winn SR; Dudley S; Fedorov L; Rimann N; Thöny B; Harding CO Mol Genet Metab; 2020 Nov; 131(3):306-315. PubMed ID: 33051130 [TBL] [Abstract][Full Text] [Related]
14. Hepatocytes from wild-type or heterozygous donors are equally effective in achieving successful therapeutic liver repopulation in murine phenylketonuria (PKU). Hamman KJ; Winn SR; Harding CO Mol Genet Metab; 2011 Nov; 104(3):235-40. PubMed ID: 21917493 [TBL] [Abstract][Full Text] [Related]
15. Reversal of metabolic and neurological symptoms of phenylketonuric mice treated with a PAH containing helper-dependent adenoviral vector. Cerreto M; Mehdawy B; Ombrone D; Nisticò R; Ruoppolo M; Usiello A; Daniele A; Pastore L; Salvatore F Curr Gene Ther; 2012 Feb; 12(1):48-56. PubMed ID: 22348550 [TBL] [Abstract][Full Text] [Related]
16. Characterization of transgenic mice with the expression of phenylalanine hydroxylase and GTP cyclohydrolase I in the skin. Christensen R; Alhonen L; Wahlfors J; Jakobsen M; Jensen TG Exp Dermatol; 2005 Jul; 14(7):535-42. PubMed ID: 15946242 [TBL] [Abstract][Full Text] [Related]
17. Reconstitution of enzymatic activity in hepatocytes of phenylalanine hydroxylase-deficient mice. Liu TJ; Kay MA; Darlington GJ; Woo SL Somat Cell Mol Genet; 1992 Jan; 18(1):89-96. PubMed ID: 1312261 [TBL] [Abstract][Full Text] [Related]
18. Reversal of hypopigmentation in phenylketonuria mice by adenovirus-mediated gene transfer. Nagasaki Y; Matsubara Y; Takano H; Fujii K; Senoo M; Akanuma J; Takahashi K; Kure S; Hara M; Kanegae Y; Saito I; Narisawa K Pediatr Res; 1999 Apr; 45(4 Pt 1):465-73. PubMed ID: 10203136 [TBL] [Abstract][Full Text] [Related]
19. Use of an adeno-associated virus serotype Anc80 to provide durable cure of phenylketonuria in a mouse model. Kaiser RA; Weber ND; Trigueros-Motos L; Allen KL; Martinez M; Cao W; VanLith CJ; Hillin LG; Douar A; González-Aseguinolaza G; Aldabe R; Lillegard JB J Inherit Metab Dis; 2021 Nov; 44(6):1369-1381. PubMed ID: 33896013 [TBL] [Abstract][Full Text] [Related]
20. Comparison of adeno-associated virus pseudotype 1, 2, and 8 vectors administered by intramuscular injection in the treatment of murine phenylketonuria. Rebuffat A; Harding CO; Ding Z; Thöny B Hum Gene Ther; 2010 Apr; 21(4):463-77. PubMed ID: 19916803 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]